

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Application Number	10/717,296	
Filing Date	November 19, 2003	
First Named Inventor	Davin C. Dillon	
Art Unit		
Examiner Name		
Attorney Docket No.	210121.491C8	

ENCLOSURES (check all that apply)									
Extension of Tolerand Express Aband Request Information Dis Statement; For Cited Reference Certified Copy Document(s) Response to Munder 37 C.F.F. Response to Mean Parts/Incompleted	al Form ned esponse declaration(s) ime Request donment sclosure rm PTO-1449 ces of Priority dissing Parts R. 1.52 or 1.53 dissing	Drawing(s) Request for Corrected Filing Receipt Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation, Change of Correspondence Address Declaration Statement under 37 CFR 3.73(b) Terminal Disclaimer Request for Refund	CD(s), Number of CD(s) After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Return Receipt Postcard Additional Enclosure(s) (please identify below):						
<u>Remarks</u>									
	SIGNATUR	RE OF APPLICANT, ATTORNEY, (OR AGENT						
Individual Name		iter, Ph.D., Patent Agent	Customer Number 00500						
Signature	Chel	re Chrat							
Date	December 8	, 2003							
	CERI	TIFICATE OF TRANSMISSION/MA	ILING						
with the United Sta	at this correspondence	ondence is being facsimile transmitt rvice with sufficient postage as first r Patents, P.O. Box 1450, Alexandri	ed to the USPTO or deposited class mail in an envelope						
Typed or printed r	name Lav	vrence Teague							
Signature This collection of information i	s required by 87 CFR 1	5. The information is required sobtain or retain a benefit i	Date: December 5, 2003 by the public which is to file (and by the USPTO to						
process) an application. Conf	identiality is governed b	y 35 U.S.C. 122 and 37 CFR 134. This collection is estimated	ated to take 12 minutes to complete, including gathering,						

Inis collection of information is sequired by 87 CFR 1.5. The information is prequired postation or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 14. This collection is estimated to take 12 minutes to complete, including gathering preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.





I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

December 8 2003

Date

Lawrence Teague

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Davin C. Dillon et al.

Application No.

10/717,296

Filed

November 23, 2003

For

COMPOSITIONS AND METHODS FOR THE THERAPY AND

DIAGNOSIS OF BREAST CANCER

Docket No.

210121.491c8

Date

December 8, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached forms PTO-1449. This application is a continuation-in-part and relies, under 35 U.S.C. § 120, on the earlier filing date of prior application U.S. Patent Application No. 10/010,742 filed November 30, 2001; which is a continuation-in-part of U.S. Patent Application No. 09/910,689, filed July 20, 2001, now abandoned; which is a continuation-in-part of U.S. Patent Application No. 09/778,320, filed February 6, 2001; which is a continuation-in-part of U.S. Patent Application No. 09/571,025, filed May 15, 2000, now abandoned; which is a continuation-in-part of U.S. Patent Application No. 09/571,025, filed May 15, 2000, now abandoned; which is a

continuation-in-part of U.S. Patent Application No. 09/523,586, filed March 10, 2000 now abandoned; which is a continuation-in-part of U.S. Patent Application No. 09/510,662, filed February 22, 2000; which is a continuation-in-part of U.S. Patent Application No. 09/451,651, filed November 30, 1999, now Patent No. 6,489,101. The references listed on the attached forms PTO-1449 were submitted to and/or cited by the Office in these prior applications and, therefore, are not required to be provided in the present application. If the Examiner wishes, copies of the references will be provided upon request.

As to any reference previously supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC

Julie A. Urvater, Ph.D., Patent Agent

Registration No. 50, 461

JAU:ljt Enclosures:

-

Postcard Transmittal Form Forms PTO-1449 (3 sheets)

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031

\438828

FORM PTO-1449 (REV.7-80)



APPLICATION NO. ATTY. DOCKET NO. 210121.491C8 10/717,296

APPLICANTS

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Davin C. Dillon et al. FILING DATE GROUP ART UNIT November 19, 2003

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,654,172	08/05/97	Li et al.	435	69.1	
	AB	2003/0022334	01/30/03	Glucksmann	435	189	
	AC	ac 2003/0027988 02/06/03		Baker et al.	530 350		
	AD						
	AE						
	AF						
	AG						
	AH						
	Al						

FOREIGN PATENT DOCUMENTS

	DOCUMENT	DATE	COUNTRY		LATION
	NUMBER	DATE	COOKIKI	YES	NO
LΑ	WO 96/06862	03/07/96	WIPO		
AK	WO 97/25431	07/17/97	WIPO		
AL	WO 99/00408	01/07/99	WIPO		
AM	WO 99/14230	03/25/99	WIPO		
AN	WO 99/25877	05/27/99	WIPO		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AO	 Burger et al., "Breast cancer genome anatomy: correlation of morphological changes in breast carcinomas with expression of the novel gene product Di12," <i>Oncogene 16</i> :327-333, 1998.
	AP	Diatchenko et al., "Suppression subtractive hybridization: A method for generating differentially regulated or tissue-specific cDNA probes and libraries," <i>Proc. Natl. Acad. Sci. USA 93</i> :6025-6030, June 1996.
	AQ	GenBank Database, Accession No. AAW92654, April 30, 1999.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)

0		RTMENT OF COMMERCE
TE.	PATENT A	ND TRADEMARK OFFICE
AL B TH	ADEMA	

ATTY. DOCKET NO. APPLICATION NO. 210121.491C8 10/717,296

APPLICANTS

Davin C. Dillon et al.

November 19, 2003

FILING DATE

GROUP ART UNIT

(Use several sheets if necessary)

INFORMATION DISCLOSURE STATEMENT

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	, NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	BA							

FOREIGN PATENT DOCUMENTS

	DOCUMENT	DATE	COUNTRY		LATION
	NUMBER		COUNTRI	YES	NO
 ВВ	WO 99/33869	07/08/99	WIPO		
BC	WO 99/37775	07/29/99	WIPO		
BD	WO 00/12758	03/09/00	WIPO		
BE	WO 00/36107	06/22/00	WIPO		
BF	WO 01/51638	07/19/01	WIPO		
BG	WO 01/51628	07/19/01	WIPO		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

вн	GenBank Database, Accession No. AF100759, July 8, 1999.
ВІ	GenBank Database, Accession No. AJ131016, February 4, 2000.
ВЈ	GenBank Database, Accession No. AL135960, February 3, 2000.
вк	GenBank Database, Accession No. AL356793, November 29, 2001.
BL	Genseq Database (Thomason Derwent), Accession No. AAL08649, December 7, 2001.
ВМ	Genseq Database (Thomason Derwent), Accession No. AAL18673, December 7, 2001.
BN	Genseq Database (Thomason Derwent), Accession No. AAL23934, December 7, 2001.

EXAMINER

DATE CONSIDERED

* EXAMINER:

Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)

DEG	_'_	•	Loo	
o				U.S. DEPARTMENT OF COMMERCE
E.			. ત	PATENT AND TRADEMARK OFFICI
18	TF	A	DEMA	

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. APPLICATION NO. 210121.491C8 10/717,296

APPLICANTS

Davin C. Dillon et al.

(Use several sheets if necessary)						FILING DATE GROUP ART UNIT November 19, 2003								
				U.S	. PATENT	DOCUMENTS								
*EXAMINER INITIAL		DO	DOCUMENT NUMBER DATE NAME		CLASS	SUBCLASS		G DATE OPRIATE						
· · · · · · · · · · · · · · · · · · ·	CA									·				
				FOREI	IGN PATEN	NT DOCUMENTS								
•			DOCUMENT NUMBER	DATE		COUNTRY			TRANS YES	LATION NO				
	СВ													
			ОТНЕ	R PRIOR A	RT (Including	Author, Title, Date, Pertinent Pag	ges, Etc.)							
	СС		Genseq Datal	base (Thom	ason Derwe	ent), Accession No. AA	.L24582	2, December	7, 200	1.				
	CD			f CD8α in a	mast cell-d	phenotype by a novel of erived interleukin-4-de		•		ystem				
	CE					ass of GABA _A receptor of Biological Chemistry				ne 13,				
	CF		1			didate tumor-suppresso i. USA 88:2825-2829, A	_	-	⁄e					
	CG			Porter-Jordan and Lippman, "Overview of the biologic markers of breast cancer," <i>Breast Cancer</i> 8(1):73-100, February 1994.										
	СН		[-		velopment of recombinate reast Cancer Research):27-39	9,				
	CI					- 				_				
	CJ								*					
	СК													
	CL					. =-								

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).